Porton(300363)2025-05-25 15:42Group 1: Strategic Focus - The company's strategic focus for 2025 is on overseas markets, which account for approximately 75% of its business, and cornerstone business segments that contribute about 90% of revenue [1] - New business segments primarily target domestic customers, with ongoing efforts to develop overseas markets in molecular business and gene cell therapy [1] Group 2: Market Presence and Operations - The company does not have separate operational entities in Japan and South Korea but has business development efforts in these markets, which have shown promising growth since 2024 [2] - The Slovenia R&D and production base serves global clients, with a core customer base primarily from Europe [2] Group 3: Order and Delivery Insights - The average order delivery cycle ranges from 3 to 18 months, depending on project requirements, with no significant seasonal delivery patterns [2] - Specific data on Q1 2025 orders was not disclosed due to reporting constraints [2] Group 4: Financial Performance and Projections - The revenue from the formulation business declined by 40% in Q1 2025, primarily due to project delivery timing [3] - The company's gross margin is in a recovery phase, with the core business segment of small molecule APIs maintaining a gross margin of approximately 33% in 2024 [3] - The company aims to enhance revenue scale and introduce more high-value projects to optimize product structure and improve operational efficiency for sustained gross margin recovery [3]